MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

Kymera Therapeutics Inc

Open

SectorGezondheidszorg

56.95 3.06

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

54.81

Max

58.9

Belangrijke statistieken

By Trading Economics

Inkomsten

-11M

-77M

Verkoop

-11M

11M

EPS

-0.95

Winstmarge

-667.602

Werknemers

218

EBITDA

-21M

-85M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+17.33% upside

Dividenden

By Dow Jones

Volgende Winsten

31 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.5B

4.2B

Vorige openingsprijs

53.89

Vorige sluitingsprijs

56.95

Nieuwssentiment

By Acuity

50%

50%

149 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Kymera Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 nov 2024, 03:00 UTC

Top Nieuws

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

Peer Vergelijking

Prijswijziging

Kymera Therapeutics Inc Prognose

Koersdoel

By TipRanks

17.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 64.13 USD  17.33%

Hoogste 88 USD

Laagste 53 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kymera Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

17

Buy

0

Hold

0

Sell

Technische score

By Trading Central

28.34 / 33.56Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

149 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat